PKPD

Sutimlimab exposure and hemoglobin response

A two-compartment PK/PD model coupling sutimlimab linear and nonlinear disposition to concentration-dependent recovery and turnover of hemoglobin.

Explore and simulate

Therapeutic: Sutimlimab
Target: Not reported
Disease: Cold agglutinin disease

Biological model

A two-compartment PK/PD model coupling sutimlimab linear and nonlinear disposition to concentration-dependent recovery and turnover of hemoglobin.

Biological schematic for Sutimlimab exposure and hemoglobin response — Biology-first schematic of the model structure.

Model details

A two-compartment PK/PD model coupling sutimlimab linear and nonlinear disposition to concentration-dependent recovery and turnover of hemoglobin.

Modeled states

auc h ug mlh*ug/mL

Modeled dynamic state for auc h ug ml.
central mgmg

Modeled dynamic state for central mg.
elapsed hh

Modeled dynamic state for elapsed h.
hb g dlg/dL

Modeled dynamic state for hb g dl.
peripheral mgmg

Modeled dynamic state for peripheral mg.

Key readouts

Central sutimlimab concentrationunknown

Model-derived readout for central sutimlimab concentration.
Hemoglobing/dL

Model-derived readout for hemoglobin.
Sutimlimab pharmacodynamic effectunknown

Model-derived readout for sutimlimab pharmacodynamic effect.
Cumulative sutimlimab exposureh*ug/mL

Model-derived readout for cumulative sutimlimab exposure.
below 100 proxy percentunknown

Model-derived readout for below 100 proxy percent.

Explore this model

Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.

Starting configuration

Approved 6.5 g regimen, 65 kg

How does sutimlimab exposure translate into the onset and maintenance of hemoglobin response? Explore this intervention regimen through Central sutimlimab concentration, Hemoglobin, Sutimlimab pharmacodynamic effect, Cumulative sutimlimab exposure. This is a mechanistic product exploration, not a paper-result reproduction.

Questions to explore

How does sutimlimab exposure translate into the onset and maintenance of hemoglobin response?

Starting result

This result reflects the starting settings. Run your changes to update it.

This scenario result is temporarily unavailable.

Model inputs

Five scientist-facing controls at most.

table3 cl ml h Model parameter controlling table3 cl ml h. mL/hourtable3 vc l Model parameter controlling table3 vc l. Ltable3 vmax mg h Model parameter controlling table3 vmax mg h. mg/hourtable4 ec50 ug ml Model parameter controlling table4 ec50 ug ml. ug/mLtable4 turnover time h Model parameter controlling table4 turnover time h. hour

Compare a parameter

How does one model input change the response?

How does sutimlimab exposure translate into the onset and maintenance of hemoglobin response?

Parameter to compare

table3 cl ml h

Model parameter controlling table3 cl ml h.

Exploratory range around the default value.

Low High Points

5 evenly spaced values in mL/hour. Other model inputs and the simulation window stay fixed.

Interpret with care

Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.
Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario.

Review the server-confirmed fixed price before starting the comparison.

Comparative response

End-of-window response across the selected parameter values.

Choose an exploratory range around the default, review the fixed price, and run the comparison.

Scientific reference

Supporting publication

Sutimlimab Pharmacokinetics and Pharmacodynamics in Patients with Cold Agglutinin Disease

The Journal of Pharmacology and Experimental Therapeutics